Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: Pechala's Reports
$25.00
Provider: Pechala's Reports
$15.00
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

OPKO Health Inc announces positive interim six-month Lagova (hGH-CTP) Phase 2 data in pediatric growth hormone deficiency disorder


Monday, 23 Jun 2014 02:00pm EDT 

OPKO Health Inc:Says six month results of Phase 2 dose-finding study evaluating the safety and efficacy of its long-acting human growth hormone product (Lagova) to treat pediatric growth hormone deficiency disorder (GHD).All three Lagova once-weekly doses demonstrate strong catch-up growth during the six months treatment.Annualized growth rates are above 12 cm in all three doses.Results are supported by excellent dose dependent pharmacokinetics (PK) and pharmacodynamics (PD) profiles.Lagova shows promising safety profile with no serious adverse events reported.Glucose and lipid metabolism markers are within the normal ranges.No lipoatrophy was observed in any patients dosed, and no clinically significant local tolerability issues were identified. 

Company Quote

14.83
0.17 +1.16%
24 Apr 2015